<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00569855</url>
  </required_header>
  <id_info>
    <org_study_id>06611</org_study_id>
    <nct_id>NCT00569855</nct_id>
  </id_info>
  <brief_title>Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery</brief_title>
  <official_title>Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arkansas Children's Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiopulmonary bypass is done with a machine that does the work of the heart and lungs
      during open-heart surgery. This study is to determine if intravenous (i.v.) phenoxybenzamine
      is safe. This drug lowers the blood pressure, making it easier for the cardiopulmonary bypass
      machine to deliver blood and oxygen to all of the organs and tissues.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Had Significant Hypotension as Defined in the Protocol as Need for Norepinephrine Dose &gt;0.1mcq/kg/Min in the First 72 Hours Postoperatively</measure>
    <time_frame>72 hours postoperatively</time_frame>
    <description>Number of subjects who required Norepinephrine &gt;0.1mcq/kg/min</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">785</enrollment>
  <condition>Open-heart Surgery</condition>
  <condition>Cardiopulmonary Bypass</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive phenoxybenzamine in preparation for cardiopulmonary bypass during open-heart surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenoxybenzamine</intervention_name>
    <description>0.125 to 1 mg/kg given i.v. over 15 to 45 minutes in preparation for cardiopulmonary bypass; may be continued at 0.125 mg/kg/day in ICU</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Dibenzyline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  0-18 years of age

          -  weight of less than or equal to 20 kilograms

        Exclusion Criteria:

          -  Parental refusal to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michiaki Imamura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arkansas Childrens Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2007</study_first_submitted>
  <study_first_submitted_qc>December 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2007</study_first_posted>
  <results_first_submitted>January 12, 2011</results_first_submitted>
  <results_first_submitted_qc>February 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 1, 2011</results_first_posted>
  <last_update_submitted>February 3, 2011</last_update_submitted>
  <last_update_submitted_qc>February 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Carole Hamon</name_title>
    <organization>University of Arkansas for Medical Sciences</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenoxybenzamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The patient population eligible for enrollment included those pediatric patients 20 kilograms or less in weight undergoing open-heart surgery requiring extracorporeal circulation (cardiopulmonary bypass) at Arkansas Childrenâ€™s Hospital, regardless of their gender or ethnic background</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Subjects Who Received Study Drug</title>
          <description>Subjects less than 20 kgs who received phenoxybenzamine in preparation for cardiopulmonary bypass during open-heart surgery with a dose range between 0.125mg/kg to 0.5mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="785">832 subjects enrolled; however, study records only available for analysis from 2004 =446 subjects</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="785">785 subjects treated with study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects Who Received Study Drug</title>
          <description>Subjects less than 20 kgs who received phenoxybenzamine in preparation for cardiopulmonary bypass during open-heart surgery with a dose range between 0.125mg/kg to 0.5mg/kg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="785"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had Significant Hypotension as Defined in the Protocol as Need for Norepinephrine Dose &gt;0.1mcq/kg/Min in the First 72 Hours Postoperatively</title>
        <description>Number of subjects who required Norepinephrine &gt;0.1mcq/kg/min</description>
        <time_frame>72 hours postoperatively</time_frame>
        <population>No. of subjects consented = 832; 785 subjects received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Who Received Study Drug</title>
            <description>Subjects less than 20 kgs who received phenoxybenzamine in preparation for cardiopulmonary bypass during open-heart surgery with a dose range between 0.125mg/kg to 0.5mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Significant Hypotension as Defined in the Protocol as Need for Norepinephrine Dose &gt;0.1mcq/kg/Min in the First 72 Hours Postoperatively</title>
          <description>Number of subjects who required Norepinephrine &gt;0.1mcq/kg/min</description>
          <population>No. of subjects consented = 832; 785 subjects received study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="785"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Subjects Who Received Study Drug</title>
          <description>Subjects less than 20 kgs who received phenoxybenzamine in preparation for cardiopulmonary bypass during open-heart surgery with a dose range between 0.125mg/kg to 0.5mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>death</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Early Death- defined as death within 72 hours of treatment with study drug</sub_title>
                <description>AE=early death as defined as death within 72 hours of treatment; cause of death was not analyzed.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Research Program Manager, Cardiovascular Surgery, Dept. of Pediatrics</name_or_title>
      <organization>University of Arkansas, Arkansas Children's Hospital, Dept. of Pediatrics</organization>
      <phone>501-364-1100 ext 5859</phone>
      <email>althagekarena@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

